Quantum BioPharma Ltd. (QNTM) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.15
↑+64% vs avg
5yr avg: 1.92
30Y Low0.4·High6.8
ROE
↓
-337.0%
↑-150% vs avg
5yr avg: -135.0%
30Y Low-337%·High-56%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
QNTM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Quantum BioPharma Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $20M | $24M | $4M | $36M | $31M | $36M | $19M | $38M | $254M | — | — |
| Enterprise Value | $20M | $24M | $-987077 | $34M | $14M | $940333 | $2M | $34M | $238M | — | — |
| P/E Ratio → | -0.60 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.15 | 4.71 | 0.40 | 2.82 | 1.00 | 0.66 | 0.52 | 1.06 | 6.78 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
QNTM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
QNTM Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -337.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 100.0% | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | -13586.0% | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | -13586.0% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -337.0% | -337.0% | -121.7% | -82.4% | -55.8% | -78.0% | -87.6% | -106.1% | -70.4% | -57.1% | — |
| ROA | -185.2% | -185.2% | -82.1% | -64.1% | -46.6% | -67.3% | -74.7% | -95.5% | -67.2% | -51.5% | -637.3% |
| ROIC | -222.1% | -222.1% | -153.6% | -145.2% | -122.8% | -130.7% | -89.9% | -62.6% | — | -69.6% | — |
| ROCE | -197.0% | -197.0% | -138.2% | -109.4% | -64.7% | -74.4% | -84.3% | -60.9% | — | -57.1% | — |
QNTM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.08 | 0.03 | 0.02 | 0.01 | 0.01 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.50 | -0.19 | -0.54 | -0.64 | -0.47 | -0.12 | -0.41 | -0.38 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -42.57 | -42.57 | -312.50 | -60970.87 | -545.96 | -487.99 | -119.77 | -218.43 | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($2M)
QNTM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.07x means Quantum BioPharma Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.43x to 1.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.07 | 1.80 | 2.43 | 2.28 | 5.28 | 4.82 | 1.25 | 12.94 | 4.26 | 0.12 |
| Quick Ratio | 1.06 | 1.06 | 1.79 | 2.43 | 2.28 | 5.28 | 4.82 | 1.15 | 12.94 | 4.26 | 0.12 |
| Cash Ratio | 1.02 | 1.02 | 1.08 | 0.77 | 2.17 | 4.07 | 3.14 | 0.87 | 12.12 | 3.74 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — | 2.88 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | 4143.64 | — |
QNTM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Quantum BioPharma Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $3M | $1M | $609056 | $595882 | $537618 | $185291 | $108557 | $90848 | $101001 | $101001 |
Peer Comparison
Compare QNTM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 QNTMYou | $20M | -0.6 | — | — | — | — | -337.0% | -222.1% | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 ANVS | $62M | -1.6 | — | — | — | — | -0.3% | — | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CMPS | $952M | -3.2 | — | — | — | — | -565.3% | — | — |
 ATAI | $969M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 LWAY | $390M | 28.8 | 19.1 | — | 27.4% | 7.6% | 17.6% | 17.8% | 0.0 |
 ABBV | $356B | 85.0 | 14.9 | 20.0 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $533B | 38.2 | 18.5 | 26.9 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.1% | -33.9% | -11.1% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
See QNTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNTM vs SAVA
Side-by-side business, growth, and profitability comparison vs Cassava Sciences, Inc..
Start ComparisonQNTM — Frequently Asked Questions
Quick answers to the most common questions about buying QNTM stock.
What is Quantum BioPharma Ltd.'s P/E ratio?
Quantum BioPharma Ltd.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is Quantum BioPharma Ltd.'s ROE?
Quantum BioPharma Ltd.'s return on equity (ROE) is -337.0%. The historical average is -110.7%.
Is QNTM stock overvalued?
Based on historical data, Quantum BioPharma Ltd. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.